1 / 31

Evaluating Ultrafiltration in Heart Failure: Study Design and Key Outcomes

This study investigates the effects of ultrafiltration treatment in heart failure patients, aiming to evaluate primary endpoints such as weight loss and dyspnea score at 48 hours. Secondary endpoints include net fluid loss, worsening heart failure within 90 days, and freedom from rehospitalization. The study outlines methods for inclusion and exclusion criteria, procedures, statistical analyses, and safety endpoints such as serum creatinine changes and adverse events. The findings will contribute to understanding the efficacy and safety of ultrafiltration in managing heart failure.

blythe
Télécharger la présentation

Evaluating Ultrafiltration in Heart Failure: Study Design and Key Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Investigators & Sites

  2. Background

  3. Study Hypotheses

  4. Primary End Points

  5. Secondary End Points

  6. MethodsInclusion Criteria

  7. MethodsExclusion Criteria

  8. MethodsStudy Procedures

  9. MethodsStudy Procedures

  10. MethodsUltrafiltration Device

  11. MethodsStatistical Analysis

  12. Baseline Demographics and Comorbidities

  13. Baseline Heart Failure Characteristics

  14. Baseline Functional Capacity and Vital Signs

  15. Baseline Laboratory Values

  16. Baseline Medications

  17. Primary End PointWeight Loss at 48 Hr Primary End PointWeight Loss at 48 Hr

  18. Primary End PointDyspnea Score at 48 Hr

  19. Secondary End PointNet Fluid Loss at 48 Hr

  20. Worsening Heart Failure in 90 days

  21. Freedom From Re-hospitalization for Heart Failure

  22. Secondary End Points

  23. Safety End Points: Change in Serum Creatinine

  24. Adverse events up to 90 days

  25. Deaths up to 90 days

  26. Safety End Points

  27. Vasoactive Drugs Requirement

  28. Summary

  29. Conclusions

More Related